Will President Trump nix the Cuban biotech revolution?

In March 2016, Barack Obama became the first US President to visit Cuba since 1928, marking one of the final stages in a progressive thaw in relations that, it was hoped, would usher in a new era of trade and cooperation between the two countries.

While much of the focus was on the diplomatic implications and the potential for fewer restrictions on tourism, American businesses, including those in the life sciences industry, have observed the detente with great anticipation.

At a time of historic change for Cuba and its relations with the USA, what likely ramifications are there for the pharma and biotech sectors, and could the new administration scotch President Obama’s efforts before they get off the ground?